A regular DVA patient disputed the pricing and eligibility of several medicines, believing they should all be supplied under the Repatriation Pharmaceutical Benefits Scheme (RPBS). The situation was complicated by a combination of paper prescriptions, electronic prescriptions, special-order medicines, app-related misunderstandings, and differing expectations regarding DVA entitlement. The case highlighted the importance of understanding prescription requirements, communicating regulatory limitations, and maintaining professional boundaries when faced with repeated challenges.